International Journal of Environmental Research and Public Health,
Год журнала:
2021,
Номер
18(10), С. 5227 - 5227
Опубликована: Май 14, 2021
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
one
of
the
most
frequent
causes
chronic
in
Western
world,
probably
due
to
growing
prevalence
obesity,
metabolic
diseases,
and
exposure
some
environmental
agents.
In
certain
patients,
simple
hepatic
steatosis
can
progress
non-alcoholic
steatohepatitis
(NASH),
which
sometimes
lead
cirrhosis
its
complications
including
hepatocellular
carcinoma.
Understanding
mechanisms
that
cause
progression
NAFLD
NASH
crucial
be
able
control
advancement
disease.
The
main
hypothesis
considers
it
multiple
factors
act
together
on
genetically
predisposed
subjects
suffer
from
insulin
resistance,
nutritional
factors,
gut
microbiota,
genetic
epigenetic
factors.
this
article,
we
will
discuss
epidemiology
NAFLD,
overview
several
topics
influence
development
possible
complications.
Clinical Research in Cardiology,
Год журнала:
2020,
Номер
110(7), С. 921 - 937
Опубликована: Июль 21, 2020
Abstract
Non-alcoholic
fatty
liver
DISEASE
(NAFLD)
is
the
most
common
chronic
disease
in
Western
countries
and
affects
approximately
25%
of
adult
population.
Since
NAFLD
frequently
associated
with
further
metabolic
comorbidities
such
as
obesity,
type
2
diabetes
mellitus,
or
dyslipidemia,
it
generally
considered
hepatic
manifestation
syndrome.
In
addition
to
its
potential
cause
liver-related
morbidity
mortality,
also
subclinical
clinical
cardiovascular
(CVD).
Growing
evidence
indicates
that
patients
are
at
substantial
risk
for
development
hypertension,
coronary
heart
disease,
cardiomyopathy,
cardiac
arrhythmias,
which
clinically
result
increased
mortality.
The
natural
history
variable
vast
majority
will
not
progress
from
simple
steatosis
fibrosis
end
stage
disease.
However,
progressive
forms
NAFLD,
including
non-alcoholic
steatohepatitis
(NASH)
and/or
advanced
fibrosis,
well
concomitant
types
highest
CVD.
This
review
describes
underlying
pathophysiological
mechanisms
linking
CVD,
discusses
role
a
dysfunction
factor,
focuses
on
manifestations
patients.
